Physician profile
Thomas T Su
NPI 1346417276
$9,829.90
in general payments reported to CMS, 2019-2025
38 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $304 · 2021: $1,137 · 2022: $1,409 · 2023: $1,887 · 2024: $2,189 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,831.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,277.44 | 2021-2025 | |
| Abbvie INC. | $1,013.91 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $951.41 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $834.65 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $779.92 | 2019-2025 | |
| Ucb, INC. | $760.73 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $692.62 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Sun Pharmaceutical Industries INC. | $543.15 | 2019-2025 | Ilumya |
| Pfizer INC. | $495.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $479.97 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $318.64 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $161.78 | 2021-2024 | Otezla |
| Incyte Corporation | $150.18 | 2023-2025 | Opzelura |
| Prugen, INC. Pharmaceuticals | $133.17 | 2019-2020 | |
| Dermavant Sciences, INC. | $114.57 | 2022-2024 | Vtama |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.